Advanced Science (Jul 2024)

Catalytic Dual‐Mode Immunotherapy: Anisotropic AuPt Heterostructure Decorated with Starry Pt Nanoclusters for Robust Cancer Photometalloimmunotherapy

  • Wei Bian,
  • Xi Hu,
  • Ruixue Xiao,
  • Rui Yao,
  • Bo Zhang,
  • Mingjian Zhu,
  • Tianqi Liu,
  • Yamin Liu,
  • Jing Li,
  • Peihua Lin,
  • An Xie,
  • Fangyuan Li,
  • Daishun Ling

DOI
https://doi.org/10.1002/advs.202403116
Journal volume & issue
Vol. 11, no. 28
pp. n/a – n/a

Abstract

Read online

Abstract To overcome current limitations in photoimmunotherapy, such as insufficient tumor antigen generation and a subdued immune response, a novel photo‐/metallo dual‐mode immunotherapeutic agent (PMIA) is introduced for potent near‐infrared (NIR) light‐triggered cancer therapy. PMIA features a dumbbell‐like AuPt heterostructure decorated with starry Pt nanoclusters, meticulously engineered for enhancing plasmonic catalysis through multi‐dimensional regulation of Pt growth on Au nanorods. Under NIR laser exposure, end‐tipped Pt nanoclusters induce efficient electron‐hole spatial separation along the longitudinal axis, resulting in radial and axial electron distribution polarization, conferring unique anisotropic properties to PMIA. Additionally, starry Pt nanoclusters on the sides of Au nanorods augment the local electron enrichment field. Validated through finite‐difference time‐domain analysis and Raman scattering, this configuration fosters local electron enrichment, facilitating robust reactive oxygen species generation for potent photoimmunotherapy. Moreover, Pt nanoclusters facilitate Pt2+ ion release, instigating intranuclear DNA damage and inducing synergistic immunogenic cell death (ICD) for metalloimmunotherapy. Consequently, PMIA elicits abundant danger‐associated molecular patterns, promotes T cell infiltration, and triggers systemic immune responses, effectively treating primary and distant tumors, inhibiting metastasis in vivo. This study unveils a pioneering dual‐mode ICD amplification strategy driven by NIR light, synergistically integrating photoimmunotherapy and metalloimmunotherapy, culminating in potent cancer photometalloimmunotherapy.

Keywords